Global Fibromyalgia Market Study, 2014-2024: Marketed & Pipeline Drugs, Sales by Drug, Clinical Trials, Patent Information, Prevalence Data - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Market Spotlight: Fibromyalgia (2020)" report has been added to ResearchAndMarkets.com's offering.

This Market Spotlight report covers the Fibromyalgia market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming events, probability of success, patent information, and prevalence data, as well as presenting drug-specific revenue forecasts.

Companies Mentioned

• Allergan
• Axsome
• Pfizer

Key Takeaways

• The approved drugs in the fibromyalgia space target dopamine reuptake, norepinephrine (noradrenaline) reuptake/transporter, serotonin reuptake, and voltage-gated calcium channels. All of the marketed drugs for fibromyalgia are administered via the oral route.
• The majority of industry-sponsored drugs in active clinical development for fibromyalgia are in Phase II, with two drugs in Phase III.
• Therapies in development for fibromyalgia focus on a wide variety of targets. These drugs are most commonly administered via the oral route.
• The only high-impact upcoming event in the fibromyalgia space is topline Phase IIa trial results for ASP0819. The overall likelihood of approval of a Phase I pain asset is 7.2%, and the average probability a drug advances from Phase III is 58.6%. Drugs, on average, take 9.3 years from Phase I to approval, compared to 9.8 years in the overall neurology space.
• The distribution of clinical trials across Phase I-IV indicates that the majority of trials for fibromyalgia have been in the late phases of development, with 68% of trials in Phase III-IV, and 32% in Phase I-II.
• The US has a substantial lead in the number of fibromyalgia clinical trials globally. Germany, Spain, and the UK lead the major EU markets, while India has the top spot in Asia.
• Clinical trial activity in the fibromyalgia space is dominated by completed trials. Pfizer has the highest number of completed clinical trials for fibromyalgia, with 23 trials.
• Pfizer leads industry sponsors with the highest overall number of clinical trials for fibromyalgia, followed by Allergan.

Key Topics Covered

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

• Disease Definition
• Symptoms
• Patient Subtypes
• Risk Factors
• Diagnosis

TREATMENT

• Pharmacologic Therapies

EPIDEMIOLOGY

• Fibromyalgia Prevalence

MARKETED DRUGS

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION

• Multiple Drugs for Fibromyalgia (June 25, 2019)
• NYX-2925 for Fibromyalgia (June 10, 2019)
• NYX-2925 for Fibromyalgia (December 3, 2018)

KEY UPCOMING EVENTS

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS

• Axsome Gets Reboxetine Rights In Narcolepsy From Pfizer

PARENT PATENTS

REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE

• Sponsors By Status
• Sponsors By Phase

BIBLIOGRAPHY

• Prescription Information

APPENDIX

LIST OF FIGURES

Figure 1: Overview of pipeline drugs for fibromyalgia in the US

Figure 2: Pipeline drugs for fibromyalgia, by company

Figure 3: Pipeline drugs for fibromyalgia, by drug type

Figure 4: Pipeline drugs for fibromyalgia, by classification

Figure 5: NYX-2925 for Fibromyalgia (June 10, 2019): Phase II - Pilot Study

Figure 6: NYX-2925 for Fibromyalgia (December 3, 2018): Phase II - Pilot Study

Figure 7: Key upcoming events in fibromyalgia

Figure 8: Probability of success in the fibromyalgia pipeline

Figure 9: Licensing and asset acquisition deals in fibromyalgia, 2015-20

Figure 10: Parent patents in fibromyalgia

Figure 11: Clinical trials in fibromyalgia

Figure 12: Top 10 drugs for clinical trials in fibromyalgia

Figure 13: Top 10 companies for clinical trials in fibromyalgia

Figure 14: Trial locations in fibromyalgia

Figure 15: Fibromyalgia trials status

Figure 16: Fibromyalgia trials sponsors, by phase

LIST OF TABLES

Table 1: Marketed drugs for fibromyalgia

Table 2: Pipeline drugs for fibromyalgia in the US

Table 3: Multiple Drugs for Fibromyalgia (June 25, 2019)

Table 4: NYX-2925 for Fibromyalgia (June 10, 2019)

Table 5: NYX-2925 for Fibromyalgia (December 3, 2018)

Table 6: Historical global sales, by drug ($m), 2014-18

Table 7: Forecasted global sales, by drug ($m), 2020-24

For more information about this report visit https://www.researchandmarkets.com/r/dpdt3d